European Society for Medical Oncology (ESMO) - Articles and news items

Biosimilars create opportunities for sustainable cancer care

Blog, Z Homepage promo / 22 February 2017 / Professor Josep Tabernero, Chair of the ESMO Cancer Medicines Working Group

Dr Josep Tabernero explains the benefits of biosimilars, showing how they can create sustainable, safe and affordable access to medicine globally…

Large study shows older breast cancer patients have worse outcomes

Industry news / 13 October 2016 / Niamh Louise Marriott, Digital Content Producer

Results showed that mortality was higher in patients over 70 who were either not tested with Oncotype DX or had a recurrence score result greater than 18…

Reduced risk of NSCLC death seen in Boehringer Ingelheim’s head-to-head trial

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

The trial investigated overall survival and the reduction in risk of death (14%) was observed for patients treated with afatinib versus gefitinib…

Patient overall survival still strong three years after Novartis’ melanoma trial

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

45% of patients receiving the combination of Tafinlar + Mekinist (95% CI, 39.1%-49.8%) compared with 31% of patients who received vemurafenib monotherapy…

Daiichi Sankyo Phase 1 HER2-targeting antibody drug safe and effective to treat breast cancer

Industry news / 11 October 2016 / Niamh Louise Marriott, Digital Content Producer

DS-8201a is an investigational antibody drug conjugate comprised of a humanised anti-HER2 antibody attached by a peptide linker to a novel topoisomerase…

Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC

Industry news / 6 July 2015 / Victoria White

Results from a study on the efficacy of cetuximab plus FOLFOX chemo as second-line treatment for patients with mCRC were presented at the ESMO 2015 congress…

Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancer

Industry news / 3 July 2015 / Victoria White

The Phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)…

ESMO highlights the opportunities and challenges to come from the EU Clinical Trials Regulation

Industry news / 28 May 2015 / Victoria White

ESMO, in collaboration with EORTC, have expressed their views on the EU Clinical Trials Regulation in an official position paper…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+